Abstract
Virology is probably the most rapidly developing field within clinical laboratory medicine. Adequate diagnostic methods exist for the diagnostics of most acute viral infections. However, emergence of pathogenic viruses or virus strains and new disease associations of known viruses require the establishment of new diagnostic methods, sometimes very rapidly. In the field of chronic or persistent viral diseases, particularly those involving potential of malignant or fatal development, there is a constant need for improved differential diagnostics, monitoring, prognosis and risk assessment. Increasing understanding of disease pathogenesis also enables better patient management and personalized medicine, where companion diagnostics can offer precise and specific tools for individual care. Very often the new tools are offered by molecular diagnostic techniques, and this includes the detection of microRNAs (miRNAs). miRNAs are small regulatory RNA molecules, which regulate the expression of their target genes. They are encoded both by viruses and their host, and both can target either viral or cellular gene expression. In this review the diagnostic possibilities offered by miRNA will be discussed. The focus will be on selected viral and human miRNAs in viral diseases, and examples of miRNAs of putative diagnostic potential will be presented.
Similar content being viewed by others
Prognostic impact of laboratory diagnostics may be enhanced by the use of microRNA. |
Promising microRNA panels have been identified for differential diagnostics of hepatitis B virus-associated chronic disease and liver cancer, and for enterovirus-associated cardiomyopathy. |
The potential of viral microRNAs should be thoroughly explored in any viral disease where the detection of nucleic acids is considered clinically relevant. |
1 Outline
In this narrative review some viral and human microRNAs (miRNA) of diagnostic or prognostic potential in human diseases associated with viral infections will be discussed. This review is not exhaustive; instead, examples will be presented where the use of viral or human miRNAs may contribute to better laboratory diagnostics of severe viral diseases. The emphasis will be on miRNAs whose potential has not only been suggested in experimental systems but has also been studied in representative sets of human samples. Technical approaches and pitfalls, as well as therapeutic use of miRNAs will also be discussed.
2 MicroRNAs and Their Function
MicroRNAs are small, 18–25 nucleotide (nt) long single-stranded noncoding regulatory RNA molecules, which regulate the expression of many, if not the majority of genes. It has been estimated that the expression of at least 60 % of human genes is regulated by microRNAs [1]. In humans and other mammals, microRNA encoding genes are found both in intragenic regions and in introns of messenger RNAs (mRNAs) or within non-coding RNA (ncRNA) genes [2, 3]. All human chromosomes are known to harbor miRNA sequences, the X chromosome being the richest and the Y chromosome the poorest in miRNA genes [4]. More than one-third of human miRNAs appear in clusters, i.e. they are non-randomly located in the same DNA strand relatively close to each other and transcribed together as polycistronic transcripts [5, 6].
The canonical pathway of mammalian miRNA biogenesis is presented in Fig. 1 (modified from [7]). Primary miRNA (pri-miRNA) is transcribed from the genome by RNA polymerase II. Cleavage by Drosha, a class III RNase, produces precursor miRNA (pre-miRNA) hairpin, which is then exported from the nucleus to the cytoplasm. Pre-miRNA is further cleaved by the Dicer RNaseIII to produce 18–25 nt miRNA duplex consisting of 5′ and 3′ arms. The single-stranded functional or guide miRNA usually originates from one of these arms to produce either 5p or 3p miRNA stemming from the 5′ arm or the 3′ arm of the original hairpin, respectively. Both arms may also produce functional miRNA, in which case both 5p and 3p miRNAs are produced from the same locus. For this reason, the original nomenclature using star (*) miRNA for the nonfunctional passenger strand is now being replaced by the 5p/3p nomenclature. The functional mature miRNA is then loaded to RNA-induced silencing or RISC complex where it binds to the complementary 3′ untranslated region (UTR) of target mRNA molecules to regulate gene expression. miRNAs may also bind to the 5′ UTR or open reading frame of mRNA, or to DNA directly. Binding of miRNA to mRNA leads to downregulation of gene function by destabilization and degradation of mRNA, or by translational arrest.
MicroRNAs cause gene silencing by binding to their mRNA targets. Full complementarity is not required; a minimal requirement is complementarity of the seed sequence at nt 2–8 of mature miRNA. Many viral or plant miRNAs bind to perfectly complementary sequences in the target mRNA, which is uncommon for human or animal miRNAs. It seems that binding of a miRNA to a fully complementary sequence directs cleavage of the target mRNA [8], while partial complementarity causes repression of protein translation [9–11]. Because partial complementarity is sufficient for regulation, an individual miRNA may have hundreds of targets. However, perfect complementarity of many viral miRNAs to their target may narrow down the number of targets and increase the specificity of regulation [12].
miRNAs regulate key cellular processes such as development, cell proliferation, cell differentiation, hematopoiesis, immune responses, stress response, apoptosis and cell death, stress response, chemokine and cytokine production, neurodegeneration, and oncogenesis. miRNAs may indeed be implicated in most if not all chronic human diseases.
3 Viral MicroRNA
Many viruses are known to encode their own miRNAs [12]. Both coding and noncoding viral sequences harbor miRNA genes, which is an efficient way to package regulatory capacity into viral genomes often having small size and limited coding capacity. Viruses can thus efficiently extend their possibilities to regulate the expression of their own genes as well as host genes by encoding miRNAs. Viral miRNAs are generated by canonical (Fig. 1) or noncanonical, Drosha-independent pathways [13]. Viral miRNAs can efficiently manipulate host gene expression, because they can regulate a number of mRNA targets, and they are less likely to be recognized by the host immune system than viral proteins [14]. Known functions of viral miRNAs include regulation of viral persistence or latency and reactivation, proliferation and long-term survival of host cells despite the presence of virus, and host immune evasion contributing to establishment of infection. In addition to host gene expression, viral miRNAs may also regulate the expression of viral protein coding genes [14]. Many viral miRNAs function by immune modulation and immune evasion by direct targeting of pro-apoptotic genes and controlling viral latency, which support the establishment of viral persistence [15]. Altogether, miRNAs seem to represent yet one entity of interactions between viruses and their hosts.
miRNAs encoded by herpesviruses are the most numerous and best studied. Among them, alphaherpesviruses herpes simplex (HSV) 1 and 2, cytomegalovirus (CMV) betaherpesvirus, as well as Epstein–Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV, or human herpesvirus 8 or HHV-8) gammaherpesviruses encode a number of miRNAs, whereas Varicella Zoster virus (VZV) alphaherpesvirus encodes none [16, 17]. Among DNA tumor viruses, human polyomaviruses and adenoviruses encode miRNAs [17]. Further, we have validated human papillomaviruses (HPV) encoded miRNAs [18] (Virtanen et al., unpublished data). Putative miRNA has also been identified for hepatitis B virus (HBV) [19], and among the rare miRNA encoding RNA viruses, for human immunodeficiency virus (HIV) [20, 21] and the Ebola filovirus [22]. At present the diagnostic potential of any viral miRNA has not been fully established yet. Some considerations will, however, be presented in later sections of this article for selected virus groups.
4 Human MicroRNAs in Viral Diseases
Interplay between viruses and their hosts by mechanisms involving miRNA is yet another example of their long coexistence and coevolution. Indeed, human miRNAs have been suggested to have their evolutionary origin as an innate immune defense mechanism against viral infections [23]. Human miRNA expression is substantially dysregulated in many if not all viral infections and in chronic viral diseases [24]. Computer prediction of complementary sequences suggested that human miRNAs may have potential antiviral effects against more than 200 human viruses, and this was narrowed down by further extraction to 62 viruses from six families, mostly single-stranded RNA viruses [25]. Further, host miRNAs may influence virus replication and gene expression, as well as latency or tumorigenesis, which can be achieved by expression of cellular functional orthologs of viral miRNAs as has been shown for some herpesviruses [26]. This raises the interesting question whether host miRNAs evolved to combat viral infections or whether viruses, which evolve faster, evolved to mimic specific host miRNAs [26].
Future exploration of miRNA functions will presumably illuminate the basis for tissue specificity of viruses. For example, efficient hepatitis C virus (HCV) replication depends on the liver-specific hsa-miR-122 or miR-122 (from now on the species abbreviation hsa- for Homo sapiens will be omitted) in hepatocytes (see Sects. 9 and 15) [27]. Identification of miRNA markers of individual immunological status or host immune responses to pathogens would open a whole new field of applications to miRNA-based diagnostics and therapies. This is exemplified by miR-155, which is a key modulator of T-cell responses and seems to play a central role in the immune response to many viral and bacterial infections [28–30].
Many human miRNAs have been identified which may serve as diagnostic or prognostic markers or be useful in monitoring disease course or treatment success, although few miRNAs have been established in diagnostic practice at present. In the following sections the use of both viral and cellular miRNA markers in the diagnostics of viral diseases will be discussed.
5 Extracellular MicroRNAs: Circulating and Exosomal MicroRNAs
miRNAs can be detected in diseased tissue and site of infection, but also in various body fluids such as plasma, serum, urine, saliva, or cerebrospinal fluid. Circulating miRNAs play an important role in host-pathogen interactions and display host responses to pathogen. Circulating miRNAs in the blood may originate from peripheral blood mononuclear cells (PBMC) or may be released from diseased tissue by cytolysis, tissue injury, or within apoptotic bodies [31]. miRNAs can also be actively secreted from cells in exosomes or other microvesicles, or as RNA-protein complexes. The origin and contents of exosomal miRNAs may be different in health and disease. Exosomes can be taken up by neighboring or distant cells and the content miRNAs may modulate gene expression in recipient cells, and viral miRNAs can thus exert regulation of gene expression in cells that are not infected by the virus. In clinical practice, circulating miRNAs may provide novel biomarkers to narrow down the need of invasive sampling or costly imaging examinations to smaller patient groups. However, miRNA levels in body fluids may vary and may not reflect the levels in diseased tissues, and thus for many solid tumors miRNA or any other biomarker may have to be analyzed directly from tissue.
6 MicroRNA as a Diagnostic Tool
New or accessory methods are required in clinical practice if new pathogens or new pathogen strains emerge, novel information about known pathogens accumulate, or new disease associations are established. New antivirals are continuously being launched, some of them with novel mechanisms of action, which requires new methods to monitor disease course and success of therapy. Detection of miRNA may be one of the next new fields where a biological or technical discovery finds clinical use in laboratory medicine.
MicroRNAs are promising diagnostic markers for several reasons (modified from [32]), but their use also requires careful considerations. (1) miRNAs are stable in various body fluids including the RNase rich environment of blood, at broad pH and temperature range, and in varying laboratory and transport conditions. (2) Established quantitative PCR (qPCR) methods exist for miRNA detection, but these methods, as well as protocols to normalize and quantify miRNAs, need standardization. (3) miRNA expression profiles are specific to tissue and disease, and therefore sample material and controls have to be carefully selected. (4) Levels of circulating miRNAs in various body fluids may reflect the changes in diseases tissues, but may also differ due to different sources of circulating miRNAs. The use of body fluids would be preferable to invasive samples whenever possible.
Expression of a miRNA can be regulated by many factors, and one miRNA may have even hundreds of targets, implicating that the biomarker potential of a miRNA has to be carefully assessed to establish clinical relevance. Any individual miRNA may be a marker of several disease conditions, and the same miRNA may be upregulated in one condition and downregulated in another—even in the same individual, which presents a challenge to result interpretation. In a diagnostic context detecting presence or upregulation of a biomarker is conceptually more feasible than detecting downregulation or absence.
In order to identify miRNAs of biomarker potential, pilot profiling of miRNA expression using miRNA microarray or miRNA sequencing (miRNA-seq) in a small number of relevant samples from sick (disease) and healthy (control) individuals should be carried out. From the beginning the choice of relevant sample matrix considering the putative final diagnostic test is important. Typically, a large number of miRNAs are found regulated in any disease condition, and altogether downregulation is much more frequent than upregulation. After microarray or miRNA-seq profiling a feasible set of miRNAs are selected based on robust regulation and clinical relevance of predicted or known target mRNAs. Selected miRNAs are then clinically validated by quantitative PCR in a carefully selected and characterized sample material representing both (different stages of) disease and healthy condition and relevant sample matrix.
A number of diagnostic challenges can be identified where the possibility to apply miRNA should be explored. These include early diagnosis, triage or differential diagnostics to narrow down patients at high risk, monitoring of disease progression and treatment follow-up, risk of reactivation of chronic or latent viral infection, risk of recurrence or relapse, and prognosis of patients in cases where there is typically a long latency period between infection and disease. Further, miRNAs can be used both as drug targets and as drug molecules.
Detection of viral nucleic acids may be a sign of infection, a sign of contaminating virus without infection, or a marker of long persistence of nucleic acid in the organism even after clearance of infection. Future research will establish whether the same applies to miRNA.
7 Technical Issues
Amounts of individual miRNAs vary between sample matrices, and measured expression levels from different matrices are not comparable. Carefully selected positive and negative controls need to be included. Any miRNA has biomarker potential only if its levels can be assumed to remain stable in healthy individuals.
For most miRNA assays, total RNA is used as a template without the need to enrich for small RNAs. Individual miRNAs may be better extracted with a specific extraction method, but selection of the absolutely best extraction method for each miRNA may have to be compromised for fluent workflow. The amount of input material, weight or volume, is important for choice of extraction method. Standard sample volume rather than amount of RNA is feasible for body fluid samples in a diagnostic setting. Protein content of the sample may be an issue; for example, plasma is rich in protein but poor in miRNA, which may be challenging for efficient miRNA extraction. Established RNA extraction methods include phenol-based (e.g. Trizol, Thermo Fisher Scientific, Wilmington, DE), column-based (e.g. miRCURY, Exiqon A/S, Vedbæk, Denmark) or combination techniques (mirVana kits, Ambion, Life Technologies, Austin, TX; miRNeasy, Qiagen, Gaithersburg, MD) [33]. These methods yield RNA preparations of different degrees of purity, which may greatly affect the choice of downstream detection/quantification method and should be considered case by case. miRCURY kits yield highly pure miRNA, of better quality than Trizol or miRNeasy, and give good results in miRNA PCR assays if not too much starting material is loaded to saturate the column, or not too little to get low amounts of small RNAs [33, 34]. miRNeasy also yields good enrichment of high-quality small RNAs if starting material is not too ample, and may thus be optimal for biological fluids. Extraction method should be selected according to sample type and expected quantity of cells in the sample, and according to final use of the RNA preparation. We have successfully used mirVana for miRNA profiling in cell lines [18, 35] (Virtanen et al., unpublished data), mirVana Paris and miRCURY for body fluids and swabs [36] (Virtanen et al., unpublished data), and RecoverAll (Ambion) for formalin-fixed paraffin-embedded (FFPE) samples [18] (Virtanen et al., unpublished data). Although miRNAs are considered stable within natural matrices, their stability for quantitative diagnostic purposes in extracted RNA preparations has not yet been established.
Cellular samples offer the possibility to use endogenous control miRNAs to control the performance of sample extraction, reverse transcription (RT) and qPCR steps. One frequently used endogenous control for human miRNA assays is RNU6B small nuclear RNA, which is ubiquitously expressed at equal levels in many tissues and cells. Spike-in controls are useful to control for RT and qPCR, and for normalization. However, the stability of synthetic spike-in miRNA oligonucleotides is not as good as miRNAs in natural sample matrices, and thus spike-in controls may have to be added after sample extraction to avoid degradation in sample lysis buffer. A widely used spike-in control, also included in several commercial assays, is Caenorhabditis elegans cel-39-3p miRNA, which does not share homology with any known human miRNA [37]. The appropriate amount of spike-in control miRNAs is within the femtomole (10−15) to attomole (10−18) range.
Two types of qRT-PCR assays are broadly used in miRNA detection. TaqMan stem-loop primer based assays (Applied Biosystems, Thermo Scientific, Foster City, CA) are well established and have high sensitivity, and a large number of assays are readily available. Assays can be tailored for individual use, but the assay parameters may not be compatible with all putative miRNA sequences [18]. miRCURY LNA-enhanced primer-based assay design (Exiqon) may have more flexibility and is claimed by the manufacturer to be more specific, although in some cases at the cost of reduced sensitivity as observed in our own experiments (Virtanen et al., unpublished data). Running samples in triplicates at minimum is recommended, but there is no fixed recommendation as to how much variation between replicates should be tolerated.
A method of normalization, whether for solid tissue or body fluids, has to be selected to quantify the results [38, 39]. For body fluids which contain little or no cells a spike-in control is required. No established reference miRNAs exist for the analysis of circulating miRNAs for normalization. miR-16 and miR-93 are examples of reference miRNAs which have been used for serum samples from gastric cancer patients [40], but the appropriate reference miRNA may need to be selected according to disease and sample matrix.
Similar to mRNA expression levels, miRNA expression levels are quantified using 2ΔΔCt calculations based on normalized cycle of threshold (Ct) values in the qPCR assay. For each “sick” or “healthy” sample, each miRNA Ct is first normalized by subtracting the Ct for reference miRNA, for example cel-39-3p, to produce ΔCt (logarithmic parameters). Then ΔCt of healthy control is subtracted from ΔCt of sick individual to obtain ΔΔCt or normalized fold change of miRNA in sick versus healthy condition.
It is challenging to define a healthy condition, and it might be particularly challenging for patient follow-up or monitoring. Also clinical interpretation of thresholds, significant fold changes or significant absolute Ct values have to be established using statistical testing like paired T test or similar. Cellular and viral miRNAs may both serve as quantitative biomarkers. Only viral miRNAs may be used as qualitative biomarkers. They may reflect either present or past disease, and in both cases they may have biomarker potential (see Sect. 13), whereas miRNA as a remnant of viral expression products of a cured infection has no use as a biomarker.
8 Herpesviruses
Herpesviruses encode the majority of known viral miRNAs, and many of them are associated with viral latency [41]. EBV encoded miR-BART2-5p, 13 and 15 miRNAs in plasma have been found to associate with high morbidity and mortality of chronic active EBV infection [42]. Strong upregulation of BART1-3p, 2-5p, 5, 6-5p, 6-3p, 7, 8, 9, 14, 17-5p, 18-5p and 19-3p miRNAs in serum, targeting genes involved in cancer metastasis such as E-cadherin, correlates with EBV copy numbers in nasopharyngeal carcinoma tissue [43]. This may also apply to other EBV-associated malignancies such as Burkitt’s lymphoma, Hodgkin’s lymphoma, or gastric carcinoma. EBV-encoded miRNAs are selectively enriched in exosomes from nasopharyngeal carcinoma cells [44], and exosomal EBV miRNAs from infected lymphocytes have been shown to exert their functions in noninfected cells [45]. Human miR-155 induction in B cells in EBV type III latency and high expression level in Hodgkin’s, primary mediastinal and diffuse large cell lymphomas suggests involvement and functional importance in malignancies associated with EBV [46].
Host cell encoded miR-132 is strongly upregulated in endothelial cells infected by KSHV. miR-132 may mechanistically link inhibition of antiviral innate immune responses and induction of abnormal endothelial cell proliferation, both essential phenomena in Kaposi’s sarcoma [47].
In addition to straightforward antigen or nucleic acid detection of VZV, biomarkers to differentiate infections prone to cause serious complications such as pneumonia, central nervous system (CNS) complications such as encephalitis, or secondary bacterial infections are needed. In a pilot study, a putative marker panel miR-197, miR-629, miR-363, miR-132, and miR-122 was identified, although no careful clinical validation was carried out as yet [48]. For the time being VZV has not been reported to encoded miRNAs of its own.
9 Hepatitis B and C Viruses
Putative miRNA biomarkers among viral diseases have been most thoroughly studied for chronic diseases and liver cancer associated with HBV and hepatitis C (HCV) viruses, where new biomarkers could greatly contribute to current diagnostic methods and prognosis of disease course [49]. One HBV-encoded miRNA has been validated but its function has not yet been established [19]. HCV-encoded miRNAs have not been reported.
Natural course of HBV infection is characterized by immune tolerant, immune active, and immune inactive stages. Conversion of active to inactive hepatitis coincides with hepatitis B envelope antigen (HBeAg) seroconversion to anti-HBe antibodies (HBeAb) followed by clinical remission and lifelong inactive stage. A panel of circulating plasma miRNAs with strong correlation to HBV DNA loads, surface antigen HBsAg, and the immune stage of pediatric HBV infection was identified. The levels of miR-99a-5p, miR-122-5p, miR-122-3p, and miR-125b-5p decreased significantly over time in immune tolerant and immune active children, reflecting poor immunological control [50, 51]. A serum MiR-B index based on the combined Cq values (a measure of amplification corresponding to Ct) of hepatocellular miR-122-5p, miR-99a-5p and miR-192-5p, with subtraction of the Cq values of three endogenous internal controls miR-126-3p, miR-335-5p and miR-320a, was created. MiR-B index was claimed to identify therapy-induced or spontaneous switch from active to inactive chronic HBV infection [52].
A panel of eight serum miRNAs was identified for differentiation or early diagnosis of HBV-related hepatocellular carcinoma (HCC) patients from healthy individuals (AUC or area under curve in ROC analysis = 0.893) and from cirrhosis patients (AUC = 0.879): miR-206, 141-3p, 433-3p, 1228-5p, 199a-5p, 122-5p, 192-5p, 26a-5p. The miRNA panel can be used in preventive screening and for timely start of therapy instead of liver biopsy, and it shows better accuracy than the widely used alpha-fetoprotein (AFP) [53]. Another panel of seven serum miRNAs was established with high accuracy in the diagnosis of early HBV-related HCC: upregulation of miR-192, miR-21, and miR-801, and downregulation of miR-122, miR-223, miR-26a and miR-27a. The panel showed high accuracy in differentiating HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842) and cirrhosis (AUC = 0.884) [54]. These panels have been validated in reasonably large patient materials and show true potential for clinical implementation (Table 1).
miR-122 is a liver-specific miRNA, which may constitute 70 % of the miRNA pool in the liver [55, 56], and it is required for efficient HCV replication [27, 57]. Interference of endogenous miR-122 function as a treatment for HCV has entered clinical trial as a first miRNA-based therapy in humans (see Sect. 15). Currently HCV RNA viral load is the gold standard in diagnosing HCV infection and in monitoring drug efficacy, although it is not an optimal correlate of disease severity or progression because it may remain stable for years. Studies on the use of serum or plasma miR-122 as a marker of HCV infection [58, 59], chronic hepatitis C patients [60] or treatment response [61] have as yet remained inconclusive. Upregulation of serum miR-320c has been established in HCV infection [62], as well as serum or plasma miR-20a and miR-92a in acute and chronic hepatitis C-infected patients, and a further increase of circulating miR-20a in progressing liver fibrosis [63]. Inverse correlation of circulating miR-92a and miR-122 with fibrosis stage, and a decrease in miR-92a levels in resolving HCV infection have also been shown [63, 64], suggesting that more research is needed to establish true significance.
Human miR-21 is one of the most frequently upregulated miRNAs in many cancers including HCC [65]. Serum miR-21 is a more sensitive biomarker than AFP, which is currently used for screening and early diagnosis of HCC and as a marker of recurrent HCC [66]. miR-155, miR-26a and miR-31 may function as prognostic markers for risk stratification of recurrence and hepatocarcinogenesis [67–69].
10 HIV and HTLV-1
T-cell counts and viral loads are established but suboptimal markers for disease progression in human immunodeficiency virus 1 (HIV-1) patients on highly active antiretroviral therapy (HAART). HIV-1 encodes a miRNA miR-N367, an ortholog of human miR-192, by which the virus regulates its own transcription and replication [20, 21], but no diagnostic potential has been established. Biomarker potential for disease progression and monitoring of resistance to therapy has been suggested for miR-150, which is downregulated in PBMC of HIV-infected individuals, returned to normal levels upon successful HAART, but downregulated again if resistance to treatment develops [70, 71].
Adult T-cell leukemia/lymphoma (ATL) is an aggressive tumor caused by human T-cell leukemia virus type 1 (HTLV-1) retrovirus. It is characterized by long clinical latency, very poor prognosis and resistance to chemotherapy, and monoclonal integration of HTLV-1 provirus. It was reported in a small group of patients using FFPE samples, that downregulation of miR-145 is significantly associated with poor overall survival of ATL patients and could thus be used as a prognostic marker [72].
11 Respiratory Viruses
Most respiratory viruses are RNA viruses and they are not expected to express miRNA. Adenoviruses are DNA viruses and they do encode miRNAs which are known to be vastly enriched in exosomes [17], but there are no data as yet concerning the role of miRNA in human adenovirus-associated diseases.
Some human miRNAs have been implicated in lethal influenza A cases [73, 74], providing important information on human response to viral infection. miR-21 and miR-223 were found considerably upregulated in lethal infections by 1918 pandemic H1N1 in mice or avian H5N1 in macaques, while modest or no upregulation was seen in infections by less pathogenic influenza A [73, 74]. MiR-1260, -26a, -335*, -576-3p, -628-3p and -664 were significantly regulated in blood and in throat swabs in H1N1 infection, and may also represent therapeutic targets [75].
12 Picornaviruses
Picornaviruses with single-stranded RNA genomes are not known to encode miRNAs. Severe conditions caused by picornaviruses include enterovirus-associated cardiomyopathy, which is mostly caused by Coxsackie virus B3 or other CVBs. Some affected individuals spontaneously clear the virus and recover, while in others the virus persists and the disease progresses to heart failure [76]. Predictive biomarkers have not been established in profiling of protein coding genes, but miRNA markers were identified in CVB3 cardiomyopathy patients when other possible causes of heart problems were carefully excluded [76]. A panel of eight miRNAs was established: miR-135b-5p, miR-155, miR-190a-5p, miR-422a, miR-489-3p, miR-590, miR-601, and miR-1290 were strongly induced in persistent CVB3 cardiomyopathy as compared to clearing disease or healthy hearts in endomyocardial biopsies taken at the baseline for setting the diagnosis. Induction of these miRNAs may reduce viral RNA recognition and innate immune response to virus, as suggested by their predicted target genes. The panel may represent a true predictive biomarker to assess the risk of virus persistence and progressive clinical deterioration (Table 1), as well as a putative drug target [76].
13 Polyomaviruses
Of the 13 human polyomaviruses known to date, BK polyomavirus (BKPyV or BKV), JC polyomavirus (JCPyV or JCV), and Merkel cell polyomavirus (MCPyV) encode 5p and 3p miRNAs, which are cleaved from one common precursor transcript [26]. The 3p miRNA of both BKPyV and JCPyV share identical sequence and thus its origin is not possible to specify. Polyomavirus miRNAs reduce host antiviral immune responses in an unusual way in cis to regulate the accumulation of viral gene products which would otherwise raise host immune responses, and some also in trans to downregulate the expression of host transcripts related to immune responses [77]. Polyomavirus-encoded miRNAs seem to contribute to the establishment of viral persistence in an exceptionally robust manner among miRNAs, partially due to perfect homology to their target sequences [24]. MCPyV miRNAs seem not to present suitable biomarkers, although they are crucial in the establishment of persistence [78, 79].
New tools are required for early diagnosis and monitoring of severe conditions associated with BKPyV among renal transplant recipients. A limited number of studies including our own pilot study [36] have explored polyomavirus-encoded miRNAs in human samples. Surprisingly frequent detection of BKPyV/JCPyV 3p miRNA suggests that it may serve as a marker of past exposure to one or both of these viruses, and may even be more sensitive than serology [36, 80]. Detection of bkv-miR-B1-5p is much less frequent and tends to associate with high viral loads in blood [36, 81, 82], which suggests that it could serve in monitoring of severe BKPyV disease. Human miR-155, which seems to be a key regulator of host CD8 + T-cell responses to viral infections, was found downregulated in BKPyV positive plasma samples in our setting of just a few samples [36], calling for further studies.
Progressive multifocal leukoencephalopathy (PML), a fatal brain disease, is caused by reactivation of latent JCPyV followed by lytic virus replication in the brain. A number of studies including our own recent study [83] suggest that PML is specifically caused by rearranged neurotropic viral strains, but past exposure to JCPyV is considered key for PML risk assessment at present. Very frequent detection of jcv-miR-J1-5p in plasma, urine and CSF samples from immunosuppressed and healthy individuals, both seropositive and seronegative, suggest biomarker potential for past infection [36, 84]. The presence of 5p miRNA might be a more sensitive marker for past exposure than serology based on VP1 ELISA [36, 84], and therefore the biomarker potential of jcv-miR-J1-5p should be thoroughly investigated.
14 Papillomaviruses
Human papillomaviruses (HPV) are double-stranded DNA viruses whose replication takes place largely in the nucleus, which would suggest that they could encode miRNAs of their own. In some previous work, no HPV-encoded miRNAs could be identified [85, 86, 87, 88], whereas in another study putative miRNAs were predicted [89]. We have identified several putative HPV-encoded miRNAs by massive parallel sequencing of small RNA libraries established from both human tissue samples and from HPV-containing cell lines, and performed their biological validation [18] (Virtanen et al., submitted). However, HPV-encoded miRNAs are expressed at too low levels for biomarker use.
High quality tests exist for HPV diagnostics but prognostic markers, preferably detectable in swabs to avoid the need for biopsy, would be valuable for the triage and prognosis among HPV-positive patients. For example, downregulation of miR-424/miR-375/miR-218 in exfoliated cells is associated with severe cervical disease [90, 91]. Downregulation of miR-143 in cervical cancer tissue is associated with tumor size, lymph node metastasis and HPV 16 infection [87, 92, 93]. miR-21 is upregulated in cervical cancer [87, 94–96] and the levels were even higher in radiation-resistant cancers [96]. Intriguingly, upregulated miR-21 levels could also be seen in serum of cancer patients, making this particular miRNA a tempting biomarker for cervical and other cancers.
Downregulation of miR-218 takes place in high-risk HPV-positive penile and oral cavity squamous cell carcinoma, and prognostic value has been suggested [97, 98].
Squamous cell cancers of the head and neck region (HNSCC) comprise two different disease entities of different patient groups: HPV-positive cancers with considerably better response to treatment and better prognosis, and HPV-negative cancers with bad prognosis, often among heavy smokers. Because HPV test sensitivities have been adjusted to detect cervical disease and their ability to detect HPV in HNSCC is unknown, sensitive markers for differential diagnostics are required. Overexpression of miR-363, resulting in decreased cell migration and invasion, has been established in HPV-positive HNSCC [90, 99]. Downregulation of miR-145 in HPV-positive as compared to HPV-negative HNSCC and association with aggressive progression and poor prognosis were shown, suggesting potential for prognostic biomarker; downregulation has also been shown in cervical cancer and precursor lesions [90, 92, 100–102]. Interestingly, significant association of miR-21 was shown with poor survival in HPV-negative but not in HPV-positive HNSCC [103].
15 MicroRNA-Based Drug Therapy
As master regulators of gene and protein expression, miRNAs hold great therapeutic promise in the control of viral infections and many human diseases. Blocking upregulated—or virus-induced—miRNA with antagomir, a synthetic oligonucleotide which inhibits binding of the natural miRNA to its target, is tempting and has proven technically feasible. Replacement of downregulated miRNA function using miRNA mimetic or mimic is more challenging and may lead to undesired and unspecific consequences. Other challenges are off-target effects of miRNA-based therapy due to multitude of miRNA targets, drug delivery to correct anatomical site, effective dose, and sustained effect of treatment. The clinical value of viral miRNA manipulation requires more exploration, although some studies report inhibition of virus replication in experimental systems lacking viral miRNA expression. The effects of antiviral drugs may also be mediated by regulation of cellular miRNA function. The field of miRNA-based therapies is the fastest developing field in genomic medicine.
Indeed, the first miRNA-targeting drug to enter human clinical trial is SPC3649 or miravirsen developed by Santaris Pharma A/S to treat chronic HCV infection. Miravirsen is a locked nucleic acid (LNA) modified oligonucleotide complementary to miR-122, a hepatocyte-specific miRNA required for efficient HCV replication in the liver. miR-122 binds to two sites in the 5′ UTR of HCV RNA leading to viral RNA stabilization and promotion of viral replication [24, 27], and its function is inhibited by miravirsen binding. Miravirsen is currently in Phase IIb clinical trial. It has shown remarkable safety, efficacy and tolerance, no sign of developing resistance, and continued efficacy in experimental animal models as compared to standard treatments [104, 105]. Further, miR-34 mimics (MRX34) to treat hepatocellular carcinoma and metastatic liver cancer are in clinical trial [106]. It is intriguing that miRNA has found its first drug applications among viral diseases in hepatocellular carcinoma.
16 Conclusions
MicroRNA has made its way from discovery up to clinical trials with unprecedented speed, and the diagnostic and particularly prognostic potential of miRNA markers should be thoroughly investigated. miRNA panels established for differentiation of HBV-associated hepatocellular carcinoma from other chronic HBV-associated diseases and from healthy individuals are examples of miRNA-based biomarkers closest to clinical application. Another promising application, importantly with predictive value, is a panel of human miRNAs for differential diagnostics of enterovirus-associated cardiomyopathy. miRNAs that are regulated in several diseases may prove feasible as biomarkers, but careful validation and interpretation of expression levels in different disease states and in different sample matrices is required. One example is miR-21, which is upregulated in liver cancer, cervical cancer and in many other cancers, and for example in lethal influenza A cases, and may even be detected in serum. The biomarker capacity of miR-155, a key player in host T-cell responses to many viral and bacterial pathogens, should be explored. Commonly regulated miRNAs may provide information on an underlying microbial infection or on the overall immune status of the host.
A novel biomarker or a new diagnostic method is valuable only if it improves patient management. For future clinical use of miRNA biomarkers proper standardization of laboratory methods is key. Also, specific algorithms of result interpretation have to be established for each laboratory approach, sample matrix, and disease. The assets of miRNA biomarkers that can be envisaged at present include the use of body fluids enabling more selective invasive sampling, earlier diagnosis, and improved precision in disease monitoring and prediction of disease course. The diagnostic possibilities provided by viral and cellular miRNAs should be exploited in their full capacity.
References
Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14:1902–10.
Weber MJ. New human and mouse microRNA genes found by homology search. FEBS J. 2005;272:59–73.
Ghorai A, Ghosh U. miRNA gene counts in chromosomes vary widely in a species and biogenesis of miRNA largely depends on transcription or post-transcriptional processing of coding genes. Front Genet. 2014. doi:10.3389/fgene.2014.00100.
Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T, Margalit H. Clustering and conservation patterns of human microRNAs. Nucl Acids Res. 2005;33:2697–706.
Bentwich I. Prediction and validation of microRNAs and their targets. FEBS Lett. 2005;579:5904–10.
Starega-Roslan J, Koscianska E, Kozlowski P, Krzyzosiak WJ. The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci. 2011;68:2859–71.
Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304:594–6.
Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 2002;9:1327–33.
Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E, Filipowicz W. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 2005;309:1573–6.
Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell. 2006;21:533–42.
Grundhoff A, Sullivan CS. Virus-encoded microRNAs. Virology. 2011;411:325–43.
Tycowski KT, Guo YE, Lee N, Moss WN, Vallery TK, Xie M, Steitz JA. Viral noncoding RNAs: more surprises. Genes Dev. 2015;29:567–84.
Skalsky RL, Cullen BR. Viruses, microRNAs, and host interactions. Annu Rev Microbiol. 2010;64:123–41.
Boss IW, Renne R. Viral miRNAs: tools for immune evasion. Curr Opin Microbiol. 2010;13:540–5.
Umbach JL, Nagel MA, Cohrs RJ, Gilden DH, Cullen BR. Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia. J Virol. 2009;83:10677–83.
Kincaid RP, Sullivan CS. Virus-encoded microRNAs: an overview and a look to the future. PLoS Pathog. 2016. doi:10.1371/journal.-ppat.1003018.
Qian K, Pietilä T, Rönty M, Michon F, Frilander MJ, Ritari J, Tarkkanen J, Paulín L, Auvinen P, Auvinen E. Identification and validation of human papillomavirus encoded microRNAs. PLoS One. 2013. doi:10.1371/journal.pone.0070202.
Jin WB, Wu FL, Kong D, Guo AG. HBV-encoded microRNA candidate and its target. Comput Biol Chem. 2007;31:124–6.
Omoto S, Ito M, Tsutsumi Y, Ichikawa Y, Okuyama H, Brisibe EA, Saksena NK, Fujii YR. HIV-1 nef suppression by virally encoded microRNA. Retrovirology. 2004. doi:10.1186/1742-4690-1-44.
Omoto S, Fujii YR. Regulation of human immunodeficiency virus 1 transcription by nef microRNA. J Gen Virol. 2005;86:751–5.
Liang HW, Zhou Z, Zhang SY, Zen K, Chen X, Zhang CY. Identification of Ebola virus microRNAs and their putative pathological function. Sci China Life Sci. 2014;57:973–81.
Koppers-Lalic D, Hogenboom MM, Moddeldorp JM, Pegtel DM. Virus-modified exosomes for targeted RNA delivery: a new approach in nanomedicine. Adv Drug Deliv Rev. 2013. doi:10.1016/j.addr.2012.07.006.
Li Y, Kowdley KV. MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics. 2012;10:246–53.
Watanabe Y, Kishi A, Yachie N, Kanai A, Tomita M. Computational analysis of microRNA-mediated antiviral defense in humans. FEBS Lett. 2007;581:4603–10.
Lagatie O, Tritsmans L, Stuyver LJ. The miRNA world of polyomaviruses. Virol J. 2013. doi:10.1186/1743-422X-10-268.
Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309:1577–81.
Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P. MicroRNA-155 is required for effector CD8 + T cell responses to virus infection and cancer. Immunity. 2013;38:742–53.
Lind EF, Elford AR, Ohashi PS. Micro-RNA 155 is required for optimal CD8 + T cell responses to acute viral and intracellular bacterial challenges. J Immunol. 2013;190:1210–6.
Lind EF, Ohashi PS. Mir-155, a central modulator of T-cell responses. Eur J Immunol. 2014;44:11–5.
Mi S, Zhang J, Zhang W, Huang RS. Circulating microRNAs as biomarkers for inflammatory diseases. Microrna. 2013;2:64–72.
Jin XF, Wu N, Wang L, Li J. Circulating microRNAs: a novel class of potential biomarkers for diagnosing or prognosing central nervous system diseases. Cell Mol Neurobiol. 2013;33:601–13.
El-Khoury V, Pierson S, Kaoma T, Bernardin F, Berchem G. Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. Sci Rep. 2016. doi:10.1058/srep19529.
McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011;57:833–40.
Greco D, Kivi N, Qian K, Leivonen SK, Auvinen P, Auvinen E. Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One. 2011. doi:10.1371/journal.pone.0021646.
Pietilä T, Nummi M, Auvinen P, Mannonen L, Auvinen E. Expression of BKV and JCV encoded microRNA in human cerebrospinal fluid, plasma and urine. J Clin Virol. 2015;65:1–5.
Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50:298–301.
Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14:844–52.
Qi R, Weiland M, Gao XH, Zhou L, Mi QS. Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology. 2012;55:1640–2.
Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012;57:897–904.
Piedade D, Azevedo-Pereira JM. The role of microRNAs in the pathogenesis of herpesvirus infection. Viruses. 2016. doi:10.3390/v8060156.
Kawano Y, Iwata S, Kawada J, Gotoh K, Suzuki M, Torii Y, Kojima S, Kimura H, Ito Y. Plasma viral microRNA profiles reveal potential biomarkers for chronic active Epstein–Barr virus infection. J Infect Dis. 2013;208:771–9.
Wong AM, Kong KL, Tsang JWH, Kwong DLW, Guan XY. Profiling of Epstein–Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer. 2012;118:698–710.
Meckes DG Jr, Shair KH, Marquitz AR, Kung CP, Edwards RH, Raab-Traub N. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci USA. 2010;107:20370–5.
Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Gruijl TD, Würdinger T, Middeldorp JM. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA. 2010;107:6328–33.
Lu F, Weidmer A, Liu CG, Volinia S, Croce CM, Lieberman PM. Epstein–Barr virus-induced miR-155 attenuates NF-κB signaling and stabilizes latent virus persistence. J Virol. 2008;82:10436–43.
Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10:707–19.
Qi Y, Zhu Z, Shi Z, Ge Y, Zhao K, Zhou M, Cui L. Dysregulated microRNA expression in serum of non-vaccinated children with varicella. Viruses. 2014;6:1823–36.
Takahashi K, Yan I, Wen HJ, Patel T. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem. 2013;46:946–52.
Winther TN, Bang-Berthelsen CH, Heiberg IL, Pociot F, Hogh B. Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B. PLoS One. 2013. doi:10.1371/journal.pone.0058236.
Winther TN, Heiberg IL, Bang-Berthelsen CH, Pociot F, Hogh B. Hepatitis B surface antigen quantity positively correlates with plasma levels of microRNAs differentially expressed in immunological phases of chronic hepatitis B in children. PLoS One. 2013. doi:10.1371/journal.pone.0080384.
Brunetto MR, Cavallone D, Oliveri F, Moriconi F, Colombatto P, Coco B, Ciccorossi P, Rastelli C, Romagnoli V, Cherubini B, Teilum MW, Blondal T, Bonino F. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. PLoS One. 2014. doi:10.1371/journal.pone.0110782.
Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X, Gan J. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014. doi:10.1371/journal.pone.0107986.
Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan JP. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29:4781–8.
Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12:735–9.
Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, Zaret KS, Taylor JM. mir-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1:106–13.
Shimakami T, Yamane D, Welsch C, Hensley L, Jangra RK, Lemon SM. Base pairing between hepatitis C virus RNA and microRNA 122 3′ of its seed sequence is essential for genome stabilization and production of infectious virus. J Virol. 2012;86:7372–83.
Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011. doi:10.1371/journal.pone.0023937.
Estrabaud E, Lapalus M, Broët P, Appourchaux K, De Muynck S, Lada O, Martinot-Peignoux M, Bièche I, Valla D, Bedossa P, Marcellin P, Vidaud M, Asselah T. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression in fibrosis in patients with chronic hepatitis C. J Virol. 2014;88:6394–402.
Zhang X, Zhang Z, Dai F, Shi B, Chen L, Zhang X, Zang G, Zhang J, Chen X, Qian F, Hu Y, Yuan Z. Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C. PLoS One. 2014. doi:10.1371/journal.pone.0092112.
Su TH, Liu CH, Liu CJ, Chen CL, Ting TT, Tseng TC, Chen PJ, Kao JH, Chen DS. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci USA. 2013;110:7844–9.
Shwetha S, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Das S. Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep. 2013. doi:10.1058/srep01555.
Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB. Up-regulation of circulating miR-20a is correlated with hepatitis C virus mediated liver disease progression. Hepatology. 2013;58:863–71.
Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J, Sauerbruch T, Dienes HP, Odenthal M. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 2013;58:234–9.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microrna expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;105:2257–61.
Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, Kanto T, Doki Y, Mori M. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56:167–75.
Valastyan S, Weinberg RA. MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle. 2009;8:3506–12.
Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol. 2012;138:153–61.
Zhang Q, Pu R, Du Y, Han Y, Su T, Wang H, Cao G. Non-coding RNAs in hepatitis B or C-associated hepatocellular carcinoma: Potential diagnostic and prognostic markers and therapeutic targets. Cancer Lett. 2012;321:1–12.
Munshi SU, Panda H, Holla P, Rewari BB, Jameel S. MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy. PLoS One. 2014. doi:10.1371/journal.pone.0095920.
Reynoso R, Laufer N, Hackl M, Skalicky S, Monteforte R, Turk G, Carobene M, Quarleri J, Cahn P, Werner R, Stoiber H, Grillari-Voglauer R, Grillari J. MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. Sci Rep. 2014. doi:10.1058/srep05915.
Xia H, Yamada S, Aoyama M, Sato F, Masaki A, Ge Y, Ri M, Ishida T, Ueda R, Utsunomiya A, Asai K, Inagaki H. Prognostic impact of microRNA-145 down-regulation in adult T-cell leukemia/lymphoma. Hum Pathol. 2014;45:1192–8.
Li Y, Chan EY, Li J, Ni C, Peng X, Rosenzweig E, Tumpey TM, Katze MG. MicroRNA expression and virulence in pandemic influenza virus-infected mice. J Virol. 2010;84:3023–32.
Li Y, Li J, Belisle S, Baskin CR, Tumpey TM, Katze MG. Differential microRNA expression and virulence of avian, 1918 reassortant, and reconstructed 1918 influenza A viruses. Virology. 2011;421:105–13.
Tambyah PA, Sepramaniam S, Ali JM, Chai SC, Swaminathan P, Armugam M, Jeyaseelan K. microRNAs in circulation are altered in response to influenza A virus infection in humans. PLoS One. 2013. doi:10.1371/journal.pone.0076811.
Kuehl U, Lassner D, Gast M, Stroux A, Rohde M, Siegismund C, Wang X, Escher F, Gross M, Skurk C, Tschoepe C, Loebel M, Scheibenbogen C, Schulteiss HP, Poller W. Differential cardiac microRNA expression predicts the clinical course in human enterovirus cardiomyopathy. Circ Heart Fail. 2015;8:605–18.
Bauman Y, Mandelboim O. MicroRNA based immunoevasion mechanism of human polyomaviruses. RNA Biol. 2011;8:591–4.
Lee S, Paulson KG, Murchison EP, Afanasiev OK, Alkan C, Leonard JH, Byrd DR, Hannon GJ, Nghiem P. Identification and validation of a novel mature microRNA encoded by the Merkel cell polyomavirus in human Merkel cell carcinomas. J Clin Virol. 2011;52:272–5.
Theiss JM, Günther T, Alawi M, Neumann F, Tessmer U, Fischer N, Grundhoff A. A comprehensive analysis of replicating Merkel cell polyomavirus genomes delineates the viral transcription program and suggests a role for mcv-miR-M1 in episomal persistence. PLoS Pathog. 2015. doi:10.1371/journal.ppat.1004974.
Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ. Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects. Virol J. 2014. doi:10.1186/1743-422X-11-41.
Li JYZ, McNicholas K, Yong TY, Rao N, Coates PTH, Higgins GD, Carroll RP, Woodman RJ, Michael MZ, Gleadle JM. BK virus encoded microRNAs are present in blood of renal transplant recipients with BK viral nephropathy. Am J Transplant. 2014;14:1183–90.
Tian YC, Li YJ, Chen HC, Wu HH, Weng CH, Chen YC, Lee CC, Chang MY, Hsu HH, Yen TH, Hung CC, Yang CW. Polyomavirus BK-encoded microRNA suppresses autoregulation of viral replication. Biochem Biophys Res Commun. 2014;447:543–9.
Seppälä H, Virtanen E, Saarela M, Laine P, Paulín L, Mannonen L, Auvinen P, Auvinen E. Single-molecule sequencing reveals the presence of distinct JC polyomavirus populations in patients with progressive multifocal leukoencephalopathy. J Infect Dis. 2016. doi:10.1093/infdis/jiw399.
Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ. Viral miRNAs in plasma and urine divulge JC polyomavirus infection. Virol J. 2014. doi:10.1186/1743-422X-11-158.
Pfeffer S, Voinnet O. Viruses, microRNAs and cancer. Oncogene. 2006;25:6211–9.
Cai X, Li G, Laimins LA, Cullen BR. Human papillomavirus genotype 31 does not express detectable microRNA levels during latent or productive virus replication. J Virol. 2006;80:10890–3.
Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007;67:6031–43.
Wang X, Wang HK, Li Y, Hafner M, Banerjee NS, Tang S, Briskin D, Meyers C, Chow LT, Xie X, Tuschl T, Zheng ZM. microRNAs are biomarkers of oncogenic human papillomavirus infections. Proc Natl Acad Sci USA. 2014;111:4262–7.
Gu W, An J, Ye P, Zhao KN, Antonsson A. Prediction of conserved microRNAs from skin and mucosal human papillomaviruses. Arch Virol. 2011;156:1161–71.
Lajer CB, Garnæs E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, Rossing M, Lajer H, Svane D, Skotte L, Specht L, Buchwald C, Nielsen FC. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 2012;106:1526–34.
Tian Q, Li Y, Wang F, Li Y, Xu J, Shen Y, Ye F, Wang X, Cheng X, Chen Y, Wan X, Lu W, Xie X. MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. J Natl Cancer Inst. 2014. doi:10.1093/jnci/dju241.
Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2008;27:2575–82.
Chen Y, Ma C, Zhang W, Chen Z, Ma L. Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer. Diagn Pathol. 2014. doi:10.1186/1746-1596-9-88.
Deftereos G, Corrie SR, Feng Q, Morihara J, Stern J, Hawes SE, Kiviat NB. Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One. 2011. doi:10.1371/journal.pone.0028423.
Lee JW, Kim BG, Bae DS. MicroRNAs in cervical carcinoma. In: Cho WCS, editor. MicroRNAs in cancer translational research. New York: Springer Science + Business Media B.V; 2011. p. 189–99.
Liu S, Song L, Zhang L, Zeng S, Gao F. miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. Biochem Biophys Res Commun. 2015;459:679–85.
Barzon L, Cappellesso R, Peta E, Militello V, Sinigaglia A, Fassan M, Simonato F, Guzzardo V, Ventura L, Blandamura S, Gardiman M, Palù G, Fassina A. Profiling of expression of human papillomavirus-related cancer miRNAs in penile squamous cell carcinomas. Am J Pathol. 2014;184:3376–83.
Wu DW, Chuang CY, Lin WL, Sung WW, Cheng YW, Lee H. Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting. Carcinogenesis. 2014;35:1823–9.
Chapman BV, Wald AI, Akhtar P, Munko AC, Xu J, Gibson SP, Grandis JR, Ferris RL, Khan SA. MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. BMC Cancer. 2015. doi:10.1186/s12885-015-1888-3.
Shi M, Du L, Liu D, Qian L, Hu M, Yu M, Yang Z, Zhao M, Chen C, Guo L, Wang L, Song L, Ma Y, Guo N. Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol. 2012;228:148–57.
Miller DL, Davis JW, Taylor KH, Johnson J, Shi Z, Williams R, Atasoy U, Lewis JS Jr, Stack MS. Identification of a human papillomavirus-associated oncogenic miRNA panel in human oropharyngeal squamous cell carcinoma validated by bioinformatics analysis of the cancer genome atlas. Am J Pathol. 2015;185:679–92.
Wang Q, Qin J, Chen A, Zhou J, Liu J, Qiu J, Zhang J. Downregulation of microRNA-145 is associated with aggressive progression and poor prognosis in human cervical cancer. Tumor Biol. 2015;36:3703–8.
Ko YH, Won HS, Sun DS, An HJ, Jeon EK, Kim MS, Lee HH, Kang JH, Jung CK. Human papillomavirus-stratified analysis of the prognostic role of miR-21 in oral cavity and oropharyngeal squamous cell carcinoma. Pathol Int. 2014;64:499–507.
Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H. Therapeutic silencing of microrna-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:198–201.
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685–94.
Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA processing in human cancer. J Clin Med. 2015;4:1651–67.
Acknowledgments
Antti Auvinen is acknowledged for preparing Fig. 1.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
EA has no conflicts of interest to declare.
Funding
No financial support was received for writing this article.
Rights and permissions
About this article
Cite this article
Auvinen, E. Diagnostic and Prognostic Value of MicroRNA in Viral Diseases. Mol Diagn Ther 21, 45–57 (2017). https://doi.org/10.1007/s40291-016-0236-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40291-016-0236-x